ALFA FinderNSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,161.00
- Market cap
- ₹5,347 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 40.1×Sector 43.0×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Earnings Call Transcript: Key Takeaways
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
- Call
- Guides 40% growth
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Other results correction announcements
All →Riddhi Steel and Tube Results Correction
Riddhi Steel and Tube submitted revised unaudited half-year results to BSE, superseding the 04 November 2026 filing, to incorporate omitted GST adjustments. The revision corrects a clerical oversight in the previously reported financials.
Life Insurance Corporation of India Results Correction
LIC corrected a unit error in its November 5, 2026 results press release, changing AUM from Rs 59,60,941 lakh crore to crore. The results themselves are unchanged.
Schneider Electric Infrastructure Results Correction
Schneider Electric Infrastructure has re-filed its Q2 FY27 press release to correct a typo in the EBIT figure. Q2 sales were ₹779 crore and EBIT was ₹56 crore.
City Pulse Multiventures Results Correction
City Pulse Multiventures resubmitted its H1 results after fixing typos in balance-sheet figures. The changes are clerical, with no material impact.
Susan Electricals India Results Correction
Susan Electricals India Ltd resubmitted its standalone financial results and a revised auditor's report for the September 2026 quarter. The revision corrects a description regarding the reporting period.
Sumeet Industries Results Correction
Sumeet Industries files a corrected related party transactions statement for its Q1 FY27 integrated financial filing. The revision, filed under CIRP, is for information and record.